Tapan Kadia

Trials

Studies that name Tapan Kadia as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:55 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT07508982 · Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

  M.D. Anderson Cancer Center · recruiting · AML · principal investigator
• Ph1/Ph2
  NCT07311746 · Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

  M.D. Anderson Cancer Center · recruiting · T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia · principal investigator
• Ph3
  NCT03926624 · Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

  Delta-Fly Pharma, Inc. · terminated · Leukemia, Myeloid, Acute · principal investigator
• Ph1
  NCT03752138 · TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

  M.D. Anderson Cancer Center · withdrawn · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
• Ph2
  NCT02718755 · Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

  M.D. Anderson Cancer Center · withdrawn · Hematologic Malignancy · principal investigator
• Ph2
  NCT02462252 · Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome

  BioLineRx, Ltd. · completed · Aplastic Anemia, Hypoplastic Myelodysplastic Syndrome · principal investigator
• Ph2
  NCT01515527 · Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

  M.D. Anderson Cancer Center · recruiting · Leukemia · principal investigator
• Ph2
  NCT01191749 · Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

  M.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
• Ph1
  NCT01094860 · Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

  M.D. Anderson Cancer Center · completed · Leukemia · study chair

Grants

NIH projects from RePORTER, fetched 2026-11-12 01:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Experimental Medicine Program
  P30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026
  Named on NCT03752138